Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
Article
Google Scholar
Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center. 2022.
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.
Article
Google Scholar
Chodak G. Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol. 2006; 8 Suppl 2(Suppl 2): S3–8.
Mottet N, Bellmunt J, Briers E. Members of the EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel: EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands: EAU Guidelines Office 2021. Available at https://uroweb.org/guideline/prostate-cancer/.
Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.
Article
Google Scholar
Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, et al. Oncologic outcomes after robot-assisted radical prostatectomy: a large European single-centre cohort with median 10-year follow-up. Eur Urol Focus. 2018;4(3):351–9.
Article
Google Scholar
Pisansky TM, Thompson IM, Valicenti RK, D’Amico AV, Selvarajah S. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA Guideline Amendment 2018–2019. J Urol. 2019;202(3):533–8.
Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–46.
Article
Google Scholar
Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.
Article
Google Scholar
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–5.
Article
CAS
Google Scholar
Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64–70.
Article
CAS
Google Scholar
Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111(7):1031–6.
Article
CAS
Google Scholar
Campi R, Brookman-May SD, Subiela Henríquez JD, Akdoğan B, Brausi M, Klatte T, et al. Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European association of urology section of oncological urology. Eur Urol Focus. 2019;5(6):1029–57.
Article
Google Scholar
Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol. 2014;110(4):476–81.
Article
Google Scholar
Zhang GM, Zhu Y, Dong DH, Han CT, Gu CY, Gu WJ, et al. The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. Asian J Androl. 2015;17(5):839–44.
CAS
Google Scholar
Lefebvre F, Blanchet-Deverly A, Michineau L, Blanchet P, Multigner L, Brureau L. Metabolic syndrome and prostate cancer in Afro-Caribbean men. Prostate. 2022;82(3):359–65.
Article
CAS
Google Scholar
Eble JN, Sauter G, Epstein JI. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press. 2004; 1–353.
Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. Springer; 2010.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol. 2016;69(3):428–35.
Article
Google Scholar
Group Cmadsmss. Chinese Medical Association Diabetes Society Recommendations for Metabolic Syndrome. Chin J Diabetes. 2004;12(3):156–61.
Google Scholar
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.
Zheng X, Qiu S, Liao X, Han X, Jin K, Yang L, et al. The accumulation of metabolic syndrome components is associated with higher risk of positive surgical margin among patients with localized prostate cancer after radical prostatectomy. Onco Targets Ther. 2019;12:1613–20.
Article
CAS
Google Scholar
De Nunzio C, Simone G, Brassetti A, Mastroianni R, Collura D, Muto G, et al. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer. 2016;16:407.
Article
Google Scholar
Castillejos-Molina R, Rodríguez-Covarrubias F, Sotomayor M, Gómez-Alvarado MO, Villalobos-Gollás M, Gabilondo F, et al. Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int. 2011;87(3):270–5.
Article
Google Scholar
Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–7.
Article
CAS
Google Scholar
Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011; 34(1): 216–9.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549–80.
Article
CAS
Google Scholar
Saglam K, Aydur E, Yilmaz M, Göktaş S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol. 2003;169(4):1308–11.
Article
CAS
Google Scholar
Sousa AP, Costa R, Alves MG, Soares R, Baylina P, Fernandes R. The impact of metabolic syndrome and type 2 diabetes Mellitus on prostate cancer. Front Cell Dev Biol. 2022;10: 843458.
Article
Google Scholar
McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev. 2012;13(1):1–13.
Article
Google Scholar
Xu X, Li Q, Chang C, Wang X, Xie L. Metabolic syndrome is not associated with prostate cancer recurrence: a retrospective analysis of a Chinese cohort. Front Oncol. 2020;10:63.
Article
Google Scholar
Morlacco A, Dal Moro F, Rangel LJ, Carlson RE, Schulte PJ, Jeffrey KR. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy. Urol Oncol. 2018;36(12):528.e1-528.e6.
Article
Google Scholar
Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009;74(1):185–90.
Article
Google Scholar
De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R, Collura D, et al. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):438–45.
Article
Google Scholar
Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology. 2010;76(5):1240–4.
Article
Google Scholar
Wright JL, Plymate SR, Porter MP, Gore JL, Lin DW, Hu E, et al. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):204–8.
Article
CAS
Google Scholar
Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol. 2014;32(4):999–1005.
Article
CAS
Google Scholar
Lee H, Byun SS, Lee SE, Hong SK. Impact of poor glycemic control upon clinical outcomes after radical prostatectomy in localized prostate cancer. Sci Rep. 2021;11(1):12002.
Article
CAS
Google Scholar
Hou CP, Pan PY, Chang PL, Chen CL, Lin YH, Yang PS, et al. The impact of diabetes mellitus on patients receiving robotic assisted radical prostatectomy for prostate cancer. Urological Science. 2016;27(2):S21–S21.
Article
Google Scholar
Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–53.
Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834–40.
Article
CAS
Google Scholar
Hua Q, Zhu Y, Liu H, Ye X. Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis. Int Urol Nephrol. 2016;48(9):1437–43.
Article
CAS
Google Scholar
Zheng X, Han X, Xu H, Ai J, Yang L, Wei Q. Prognostic value of lipid profiles after radical prostatectomy: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):124.
Article
Google Scholar
Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307–18.
Article
CAS
Google Scholar
Hayashi N, Matsushima M, Yamamoto T, Sasaki H, Takahashi H, Egawa S. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU Int. 2012;109(4):515–9.
Article
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
Article
CAS
Google Scholar
Kang M, Jeong CW, Ku JH, Kwak C, Kim HH. Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy. PLoS ONE. 2015;10(3): e0122438.
Article
Google Scholar
Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am. 2011;38(3):243–59.
Article
Google Scholar
Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Giovannucci E, Wilson KM, Aspelund T, et al. Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study. Cancer. 2019;125(16):2877–85.
Google Scholar
Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, et al. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int. 2019;124(1):69–75.
Article
CAS
Google Scholar
Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012;62(5):910–6.
Article
Google Scholar
Leal-García M, Canto P, Cárdenas-Cárdenas E, Feria-Bernal G, García-García E, Méndez JP. Overweight and obesity in men with prostate cancer do not constitute risk factors for biochemical recurrence. Aging Male. 2020;23(5):1283–8.
Article
Google Scholar
Ohwaki K, Endo F, Hattori K. Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Cancer. 2015;51(5):604–9.
Article
Google Scholar
Tomaszewski JJ, Chen YF, Bertolet M, Ristau BT, Woldemichael E, Nelson JB. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy. Urology. 2013;81(5):992–6.
Article
Google Scholar
Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005; 174(5): 1798–801; discussion 1801.
Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22(3):446–53.
Article
Google Scholar
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751–6.
Article
Google Scholar
Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol. 2014;20(18):5177–90.
Article
CAS
Google Scholar